Log inSign up
AML Hub profile banner
user avatar

AML Hub

@AML_Hub
A global education platform providing clinical updates on acute myeloid leukemia. #leusm linktr.ee/AcuteMyeloidLe…
Global
aml-hub.com
Joined July 2015
2,127
Following
9,142
Followers
RepliesMedia
  • Pinned
    user avatar
    AML Hub
    @AML_Hub
    Jun 29
    🎥 In our latest expert masterclass, Mark J. Levis, Charles Craddock, and Eytan Stein discuss the current clinical landscape, key ongoing questions, and potential future directions for FLT3 inhibitors for the treatment of AML. Watch the videos here: bit.ly/4gF3zJV
    Image
  • user avatar
    AML Hub
    @AML_Hub
    Aug 18
    New publication 📝 Results from the long-term follow-up of a phase II study, published in @Haematologica, show oral decitabine/cedazuridine + venetoclax achieved an ORR of 75% in older/unfit patients with ND de novo AML vs 58% in those with ND secondary AML. Learn more about ND
    Image
  • user avatar
    AML Hub
    @AML_Hub
    Aug 13
    New publication 📝 Subgroup analysis results from the UK NCRI AML18 trial, published in @BloodPortfolio, show treatment with vs without quizartinib significantly improved OS in older patients with FLT3-mutated AML (5-year OS, 47% vs 25%; p = 0.024). Learn more about FLT3
    Image
  • user avatar
    AML Hub
    @AML_Hub
    Aug 7
    New publication 📝 Results from the phase I/II ASCERTAIN-V trial, published in @NEJM, show all-oral decitabine/cedazuridine + venetoclax had no drug–drug interactions, and achieved a CR in 47% of patients with ND AML ineligible for intensive chemotherapy in phase IIb. Learn
    Image
  • user avatar
    AML Hub
    @AML_Hub
    Jul 30
    New publication📝 Phase I KOMET-007 trial results, published in @BloodPortfolio, show ziftomenib + Ven + Aza achieved a 46% CRc rate at the recommended 600 mg ziftomenib dose, in adults with R/R NPM1-mutated AML. Learn more about NPM1-mutated AML: bit.ly/3OtuEUk #AMLsm
    Image